Asian governments are looking to Biotechnology to accelerate their food supplies and healthcare improvement, and some are even thinking about the economic growth through manufacturing valuable biological products. Companies and government agencies in Asia have been closing the gaps in regulatory compliance in manufacturing biologics in the last few years. However, countries such as China, Korea and India still lag behind in vaccine R&D and production techniques due to a lack of financial support and technology transfers from foreign companies. Emerging infectious diseases (pandemic avian influenza and global shortage of flu vaccines supply) have raised new challenges. They have changed the landscape of the vaccine industry. The processes involved in research to product launch normally take 7 to 13 years to go through multi-stage R&D and still have a low success rate. Today, novel technologies are being used and investigated for new vaccine developments.
